Jan 7, 2026 12:43AM

Sep 3, 2025 06:41AM

Sep 2, 2025 06:58AM

Jul 2, 2025 04:00PM

Jun 10, 2025 04:00PM

Jun 10, 2025 04:00PM

Apr 24, 2025 04:01PM Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanif

Feb 26, 2025 04:00PM

May 20, 2024 06:30AM

Sep 26, 2023 05:05PM

Mar 31, 2023 06:23AM

Mar 29, 2023 04:00PM

Jan 4, 2023 04:01PM

Jan 4, 2023 04:00PM Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

Dec 12, 2022 02:30AM

Nov 28, 2022 04:00PM

Nov 28, 2022 04:00PM

Nov 21, 2022 04:01PM

Nov 21, 2022 04:00PM

Nov 10, 2022 04:00PM

Oct 31, 2022 03:00AM Inventiva provides an update on the development of cedirogant by AbbVie

Oct 21, 2022 04:00PM

Sep 22, 2022 02:30AM

Sep 21, 2022 04:40PM

Mar 8, 2022 05:51AM

Mar 8, 2022 02:00AM

Mar 7, 2022 04:26PM

Mar 7, 2022 04:00PM Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis

Mar 1, 2022 04:00PM

Feb 28, 2022 04:00PM

Feb 14, 2022 04:00PM

Jan 31, 2022 04:00PM

Jan 31, 2022 04:00PM

Jan 20, 2022 04:00PM

Dec 16, 2021 04:00PM Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

Dec 6, 2021 04:00PM

Nov 10, 2021 04:00PM

Nov 3, 2021 04:00PM

Oct 27, 2021 04:00PM

Oct 20, 2021 05:07PM

Oct 18, 2021 04:00PM

Sep 28, 2021 04:00PM Inventiva announces participation at several investor conferences in October 2021

Sep 23, 2021 02:45AM

Sep 21, 2021 04:01PM

Sep 21, 2021 04:00PM

Sep 20, 2021 04:10PM

Sep 16, 2021 04:00PM

Sep 10, 2021 09:00AM

Sep 8, 2021 04:00PM Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH

Aug 30, 2021 04:00PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All